Private label famotidine
This article was originally published in The Tan Sheet
Executive Summary
Teva Pharmaceuticals receives tentative approval from FDA Oct. 15 for OTC famotidine 10 mg tablets (ANDA 75-312). The reference drug is J&J/Merck's Pepcid AC, the leading OTC stomach remedy product according to Chicago-based Information Resources, Inc. Perrigo also plans to launch a generic version of Pepcid AC when its marketing exclusivity expires Aug. 11, 2000. J&J/Merck recently launched ads for its chewable version of Pepcid AC ("The Tan Sheet" Oct. 26, In Brief). The product was approved at the end of September
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning